Anthos Therapeutics was set up by Blackstone Life Sciences after it licensed abelacimab drug from Novartis in 2019 ...
The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...
Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...
The acting chair of the, Mark Uyeda, took the first step Tuesday to rolling back a rule that would require thousands of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback